Cargando…
The problem with relying on profit-driven models to produce pandemic drugs
In this article, we explain why profit-driven models for developing treatments for epidemic pathogens produce sub-optimal and sometimes negative public health outcomes. Using the example of the drug remdesivir, we demonstrate how the divergence of private incentives from public health needs has led...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472792/ https://www.ncbi.nlm.nih.gov/pubmed/32913653 http://dx.doi.org/10.1093/jlb/lsaa060 |